SCHEMBL7069249

SCHEMBL7069249

CCCC(C(N)=O)C(CC(C)C)C(=O)N1CCN(c2cccc(Cl)c2)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.55
NPSR1 Q6W5P4 2/20 0.55
TSHR P16473 1/20 0.55
MAPK1 P28482 1/20 0.55
RECQL P46063 1/20 0.55
HTR1A P08908 1/20 0.54
HTR2A P28223 1/20 0.54
HTR7 P34969 1/20 0.54
HTR6 P50406 1/20 0.54
ALDH1A1 P00352 2/20 0.49
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
CA12 O43570 1/20 0.47
CA1 P00915 1/20 0.47
CA9 Q16790 1/20 0.47
MAPT P10636 2/20 0.47
GAA P10253 1/20 0.47
HTT P42858 1/20 0.47
PANK3 Q9H999 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7069253 1.00 LMNA (0.55) LMNANPSR1TSHRMAPK1RECQL
SCHEMBL7067097 0.89 P2RY12 (0.45) LMNANPSR1TSHRMAPK1RECQL
SCHEMBL7067098 0.89 P2RY12 (0.45) LMNANPSR1TSHRMAPK1RECQL
SCHEMBL7069855 0.89 ADAMTS5 (0.47) LMNANPSR1TSHRMAPK1RECQL
SCHEMBL7069859 0.89 ADAMTS5 (0.47) LMNANPSR1TSHRMAPK1RECQL
SCHEMBL7068679 0.88 CHIA (0.48) LMNAALDH1A1MEN1KMT2AHTT
SCHEMBL7068676 0.88 CHIA (0.48) LMNAALDH1A1MEN1KMT2AHTT
SCHEMBL7087655 0.88 GAA (0.51) LMNANPSR1TSHRMAPK1RECQL
SCHEMBL7087657 0.88 GAA (0.51) LMNANPSR1TSHRMAPK1RECQL
SCHEMBL7066754 0.88 DRD2 (0.47) LMNAMAPK1HTR1AALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030232985-A1 Succinoylamino heterocycles as inhibitors of a beta protein production THOMPSON LORIN A (US) 2003-12-18 US disclosed
US-20030073701-A1 Succinoylamino heterocycles as inhibitors of a beta protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY 2003-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073701-A1 Succinoylamino heterocycles as inhibitors of a beta protein production APP, BACE1, APH1A LMNA 911/4885NPSR1 1539/4885TSHR 4759/4885
US-20030232985-A1 Succinoylamino heterocycles as inhibitors of a beta protein production APP, BACE1, APH1A LMNA 911/4885NPSR1 1539/4885TSHR 4759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.